Regardless of Trop-2, BRCA, or HER2 Status, SG plus Pembrolizumab Significantly Improves PFS in 1L PD-L1+ mTNBC Patients: Subgroup Analysis of the ASCENT-04 Study

Regardless of Trop-2, BRCA, or HER2 Status, SG plus Pembrolizumab Significantly Improves PFS in 1L PD-L1+ mTNBC Patients: Subgroup Analysis of the ASCENT-04 Study

At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Professor Sara M. Tolaney from Dana-Farber Cancer Institute and Harvard Medical School, representing the research team, presented the latest exploratory analysis results of the ASCENT-04 study (NCT04612127). This analysis delved into the impact of biomarkers—Trop-2 expression levels, BRCA mutation status, and HER2 expression status—on the efficacy of Sacituzumab Govitecan (SG) combined with Pembrolizumab as a first-line treatment for PD-L1 positive metastatic triple-negative breast cancer (mTNBC), providing key evidence for the precise selection of benefited populations in clinical practice.
Balancing QoL Improvement Against Implant Risk: The Phase III Randomized PREPEC Trial Reveals Short- and Long-Term Benefits of Prepectoral Breast Reconstruction

Balancing QoL Improvement Against Implant Risk: The Phase III Randomized PREPEC Trial Reveals Short- and Long-Term Benefits of Prepectoral Breast Reconstruction

At a recent international academic conference, Professor Walter Weber from University Hospital Basel, Switzerland, detailed the results of the international randomized Phase III PREPEC trial (OPBC-02). The study aimed to compare the impact of two implant placement strategies—Prepectoral versus traditional Subpectoral—on the quality of life and safety of patients undergoing implant-based breast reconstruction (IBBR) following therapeutic or prophylactic mastectomy.
Overcoming the Dilemma of First-line TKI Resistance: Olverembatinib Second-line Treatment Achieves 76% CCyR in CP-CML without T315I Mutation

Overcoming the Dilemma of First-line TKI Resistance: Olverembatinib Second-line Treatment Achieves 76% CCyR in CP-CML without T315I Mutation

The treatment of Chronic Myeloid Leukemia (CML) has entered the era of Tyrosine Kinase Inhibitors (TKIs), but the choice of treatment for patients after the failure of first-line therapy remains a focus of clinical attention. Olverembatinib (HQP1351), as the first third-generation TKI independently developed in China, has previously demonstrated excellent efficacy in populations carrying the T315I mutation. However, what is the value of Olverembatinib for patients in the chronic phase (CP-CML) who do not carry the T315I mutation and have developed resistance or intolerance after first-line TKI therapy? At a recent academic conference, Professor Li Weiming from Union Hospital, Tongji Medical College, Huazhong University of Science and Technology shared the latest efficacy and safety data of Olverembatinib in the second-line treatment of CP-CML patients. This article is specially organized for readers.
EHA Echoes | Prof. Liang Wang: CD19/CD22 Dual-Target CAR-T Plus  Maintenance Therapy Breaks Through the Long-Term Survival Bottleneck in R/R LBCL

EHA Echoes | Prof. Liang Wang: CD19/CD22 Dual-Target CAR-T Plus  Maintenance Therapy Breaks Through the Long-Term Survival Bottleneck in R/R LBCL

At the 2026 Congress of the European Hematology Association (EHA), Prof. Liang Wang from Beijing Tongren Hospital, Capital Medical University, delivered an oral presentation unveiling the latest follow-up results of CAR2219, a CD19/CD22 dual-target CAR-T cell therapy for patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). The study reported an impressive 12-month progression-free survival (PFS) rate of 59.8%.
Science Without Borders, Advancing Toward Cure: EHA 2026 Opens in Stockholm, Charting a New Era of Global Collaboration and High-Quality Development in Hematology

Science Without Borders, Advancing Toward Cure: EHA 2026 Opens in Stockholm, Charting a New Era of Global Collaboration and High-Quality Development in Hematology

In June 2026, the European Hematology Association (EHA) Congress officially opened in Stockholm, Sweden, bringing together the global hematology community for one of the field’s most influential scientific events. As the largest and most prestigious annual meeting in hematology, EHA 2026 not only showcased groundbreaking scientific discoveries but also unveiled strategic initiatives that will help shape the future of hematology research and patient care over the next decade.
EHA 2026 Echoes | Hui Wang and Man Chen: Impact of Two Antithymocyte Globulin Conditioning Regimens on Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation

EHA 2026 Echoes | Hui Wang and Man Chen: Impact of Two Antithymocyte Globulin Conditioning Regimens on Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation

The 2026 Congress of the European Hematology Association (EHA 2026), held from June 11–14 in Stockholm, Sweden, brought together leading experts from around the world to showcase the latest advances in hematology research, translational medicine, and clinical practice.
EHA 2026 Echoes | Ruijuan Sun and Hai He: Allogeneic HSCT Overcomes the Poor Prognosis Associated with NUP98::NSD1-Positive Acute Myeloid Leukemia

EHA 2026 Echoes | Ruijuan Sun and Hai He: Allogeneic HSCT Overcomes the Poor Prognosis Associated with NUP98::NSD1-Positive Acute Myeloid Leukemia

The 2026 Congress of the European Hematology Association (EHA 2026) was held from June 11 to 14 in Stockholm, Sweden. As one of the most influential international meetings in hematology, EHA brings together leading experts from around the world to showcase the latest advances in basic science, translational research, and clinical practice.